SF3B1 silencing in breast cancer cell lines inhibited aberrant splicing, reducing cell proliferation, migration, and invasion, suggesting a potential antineoplastic role for SF3B1 inhibitors [178]. Here, SF3B1 is linked to breast carcinoma.